<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051933</url>
  </required_header>
  <id_info>
    <org_study_id>03-12-19B</org_study_id>
    <nct_id>NCT02051933</nct_id>
  </id_info>
  <brief_title>The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures</brief_title>
  <acronym>Botox</acronym>
  <official_title>The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Plafond (Pilon) Fractures: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if botulinum toxin type A (Botox) injections, at&#xD;
      the time of surgery for pilon fractures, will improve ankle range-of-motion and&#xD;
      functionality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if the use of Botulinum toxin A intramuscular injections of the gastrocsoleus&#xD;
      complex in patients with operatively treated tibial plafond fractures will result in:&#xD;
&#xD;
        1. increased ankle dorsiflexion when compared to controls&#xD;
&#xD;
        2. increased ankle functionality as measured by the FAAM, and quality of life as measured&#xD;
           by the SF-36, when compared to controls&#xD;
&#xD;
        3. a higher proportion of patients achieving at least 10 degrees of dorsiflexion when&#xD;
           compared to controls&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual rate&#xD;
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ankle Dorsiflexion of Injured Extremity</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>The primary outcome variable will be ankle dorsiflexion of the injured extremity as measured by equinometer device using a constant torque (10Nm) with knee fully extended and at 90 degrees of flexion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Health Related Quality of Life</measure>
    <time_frame>6 month and 12 month follow-up visits</time_frame>
    <description>SF-36 will be used to measure health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain</measure>
    <time_frame>6 month and 12 month follow-up visits</time_frame>
    <description>Overall study limb, as well as ankle specific, pain intensity will be measured using the 0-10 visual analog scale used in the Brief Pain Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional status of the Ankle</measure>
    <time_frame>6 month and 12 month follow-up visits</time_frame>
    <description>The FAAM will be obtained to assess the functional status of the affected ankle.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Equinus Contracture</condition>
  <arm_group>
    <arm_group_label>Botox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Botox intervention description</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>See Placebo Intervention Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).&#xD;
45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Botulinum toxin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).&#xD;
45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U</description>
    <arm_group_label>Botox</arm_group_label>
    <other_name>0.9% sodium chloride solution for injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 and older with a tibial plafond fracture to be treated by a staged&#xD;
             protocol involving primary external fixation and definitive fixation within 3 weeks&#xD;
             from the injury.&#xD;
&#xD;
        (Non-definitive, interval procedures such as repeat irrigation and debridement and fibular&#xD;
        fixation are allowed.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Younger than 18 years of age&#xD;
&#xD;
          -  Significant traumatic brain injury or cognitive disability that would interfere with&#xD;
             post-operative rehabilitation and study questionnaires&#xD;
&#xD;
          -  Nerve, vascular, or tendon injury of the lower leg: injury to the tibial or peroneal&#xD;
             motor nerves, injury to the posterior tibial artery requiring repair, or laceration of&#xD;
             tendons that are involved in plantar flexion or dorsiflexion of the ankle which&#xD;
             require repair&#xD;
&#xD;
          -  History of prior lower extremity fracture to the tibia or ankle of the affected limb.&#xD;
&#xD;
          -  Incarcerated patients.&#xD;
&#xD;
          -  Patients unable or unwilling to return for follow-up examination.&#xD;
&#xD;
          -  Pregnant or lactating patients.&#xD;
&#xD;
          -  History of disease affecting the neuromuscular junction (ex: myasthenia gravis).&#xD;
&#xD;
          -  Use of aminoglycoside antibiotics at the time of definitive fixation.&#xD;
&#xD;
          -  Ipsilateral foot injury that will impair dorsiflexion exercises: Lisfranc injuries,&#xD;
             fractures or dislocations of the talus, calcaneus, navicular, cuboid, cuneiforms, or&#xD;
             metatarsals (phalanx fractures or dislocations will not be excluded).&#xD;
&#xD;
          -  Patients receiving Botulinum Toxin A for other reasons.&#xD;
&#xD;
          -  Patients with a known hypersensitivity to Botulinum toxin A.&#xD;
&#xD;
          -  Gustilo Anderson type III B and C.&#xD;
&#xD;
          -  Patients with a weight greater than 115 kg - to ensure proper injection locations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhav A Karunakar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atrium Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>October 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Madhav Karunakar</investigator_full_name>
    <investigator_title>Orthopaedic Traumatologist, Department of Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <keyword>pilon</keyword>
  <keyword>tibial plafond</keyword>
  <keyword>botox</keyword>
  <keyword>ankle dorsiflexion</keyword>
  <keyword>ankle functionality</keyword>
  <keyword>ankle range of motion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contracture</mesh_term>
    <mesh_term>Equinus Deformity</mesh_term>
    <mesh_term>Talipes</mesh_term>
    <mesh_term>Clubfoot</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 9, 2017</submitted>
    <returned>September 7, 2017</returned>
    <submitted>January 25, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>February 8, 2018</submitted>
    <returned>March 8, 2018</returned>
    <submitted>October 4, 2018</submitted>
    <returned>October 30, 2018</returned>
    <submitted>June 28, 2021</submitted>
    <returned>July 15, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

